Bb biotech Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

About Bb biotech Contact Number

* Mandatory fields . We respect your privacy and do not sell, rent or loan any identifiable information collected on this site. Any information that you give us will be treated with the utmost care and security.

Contact US: https://www.bbbiotech.ch/en/bb-biotech/service/contact/

What is bb biotech?

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector with more than 25 years of experience. The shares of BB Biotech are listed on the SIX Swiss Exchange, the Frankfurt Stock Exchange and the Stock Exchange in Milan.

What is the annual report of bb biotech ag?

BB Biotech AG published its annual report for fiscal year 2020 today. Increased dividend of CHF 3.60 proposed. Loading this resource will connect to external servers which use cookies and other tracking technologies to personalize and improve experience.

Who are the largest investors in biotechnology companies?

Further information can be found in our privacy policy. BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector with more than 25 years of experience.

London

68 People Used

See More ››

BB BIOTECH

Investor Relations UK and Nordics; Phone: +44 755 704 85 77; E-Mail: [email protected] London office: BB Biotech, 32 London Bridge Street, 24th Floor, SE1 9SG, London

View Contact ››

Asset

62 People Used

See More ››

BB Biotech Ventures

Phone Number +41 44 267 67 00 BB BIOTECH VENTURES is a healthcare-dedicated venture capital fund, focused on companies that develop and market drugs and medical devices. The Guernsey–based fund is advised by the Bellevue Asset Management Group, which has operations in Curaçao, Boston/USA and Kusnacht/Zurich, Switzerland.

View Contact ››

Equity

57 People Used

See More ››

BB Biotech

Contact Email [email protected] Phone Number +41526240845 BB Biotech is an equity fund launched and managed by Bellevue Asset Management. It invests in the public equity markets across the globe.

View Contact ››

Biotech

44 People Used

See More ››

BB BIOTECH

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world''s largest investors in this sector with more than 25 years of experience. The shares of BB Biotech are listed on the SIX Swiss Exchange, the Frankfurt Stock Exchange and …

View Contact ››

Groundbreaking

65 People Used

See More ››

Shareholder information

In BB Biotech''s 2020 digital annual report, you will quickly find relevant information on the 2020 financial year, exciting stories such as about the mRNA technology, as well as trends for 2021. In particular, the video interview with Dr. Daniel Koller, Head Investment Team BB Biotech, provides you an in-depth look at the biotech industry, which has made groundbreaking achievements in the

View Contact ››

Current

66 People Used

See More ››

Shareholder information

In BB Biotech''s digital quarterly interim report 2021, you can quickly find relevant information on the current fiscal year. IE 11 is a very old Browser and it`s not …

View Contact ››

Groundbreaking

57 People Used

See More ››

Facts & Figures

In BB Biotech''s 2020 digital annual report, you will quickly find relevant information on the 2020 financial year, exciting stories such as about the mRNA technology, as well as trends for 2021. In particular, the video interview with Dr. Daniel Koller, Head Investment Team BB Biotech, provides you an in-depth look at the biotech industry, which has made groundbreaking achievements in the

View Contact ››

Report

58 People Used

See More ››

Facts & Figures

In BB Biotech''s digital quarterly interim report 2021, you can quickly find relevant information on the current fiscal year. IE 11 is a very old Browser and it`s not supported on this site Interim report as at 31.03.2021

View Contact ››

Venture

43 People Used

See More ››

Team

Venture capital investor since 2001, joined Bellevue in 2004. Co-founder and former Executive Chairman of Vaximm, a Swiss-German immuno-oncology company. Prior to Bellevue, Investment Manager at GLS Ventures in Munich. He has invested in a number of bio-pharmaceutical companies, such as Cadence, Glycart, Intercell, Vaximm and AM-Pharma.

View Contact ››

Please leave your comments here:

Popular Brands

Bmw
Bce
Boeing
Byd
Bbva